Phase 2 Study of Poziotinib in NSCLC with EGFR/HER2 Mutations Underway
A Phase 2 study is evaluating poziotinib's efficacy and safety in NSCLC patients with specific mutations.
Phase II
Oncology / NSCLC
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase 2 study of poziotinib in NSCLC patients with specific mutations is critical as it may establish the drug as a viable treatment option in a competitive landscape. Positive results could significantly enhance its market potential and influence the positioning of other therapies targeting similar mutations.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any updates on cohort performance and safety data.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.